[{"run_id":"1","name":"A_look_at_the_new_blood_tests_approved_for_Alzheimers_disease_20251021","location":"output\\A_look_at_the_new_blood_tests_approved_for_Alzheimers_disease_20251021_12","processed_ids":"1","subject":"A look at the new blood tests approved for Alzheimer's disease","provider":"gemini","model":"gemini-2.5-pro","profile":"sns_draft_v1","synthesized_article":"A Look at the New Blood Tests Approved for Alzheimer's Disease\n\nThe landscape of Alzheimer's disease diagnostics is undergoing a significant transformation. With the recent US Food and Drug Administration (FDA) approval of a second blood test designed to aid in diagnosis, clinicians and patients are gaining more accessible tools to investigate cognitive decline. These new tests represent a major step away from invasive and costly procedures, promising earlier and more widespread assessment.\n\nIn October 2025, the FDA cleared the Elecsys pTau181 test, developed by pharmaceutical companies Roche and Eli Lilly. This marks the second such approval in the same year, following the green light given to Fujirebio's Lumipulse test in May. Both tests work by detecting key biological markers of Alzheimer's in the bloodstream, but they function in slightly different ways.\n\nThe pathology of Alzheimer's is characterized by the accumulation of two proteins in the brain: amyloid-Î² plaques and tangles of a protein called tau. The new Elecsys test measures a specific modified form of tau, known as pTau181, in blood plasma. Its primary function is to help rule out Alzheimer's as the cause of a person's cognitive impairment. According to a clinical trial of 312 participants, the test was 97.9% accurate in correctly identifying individuals who did not have the disease. This makes it a powerful initial screening tool for use in primary-care settings.\n\nThe earlier approved Lumipulse test takes a different approach. It measures the ratio between two proteins, pTau217 and amyloid-Î². This allows it not only to rule out Alzheimer's but also to provide a positive indication of the disease's pathology. In its clinical trial of 499 people, the Lumipulse test showed 97% accuracy in its negative predictions and nearly 92% accuracy for its positive results when compared to follow-up diagnostic tests.\n\nThese blood-based diagnostics are being hailed as a turning point. Previously, the only definitive ways to detect amyloid and tau buildup in living patients were through a lumbar puncture to collect cerebrospinal fluid or a positron-emission tomography (PET) scan of the brain. These methods are expensive, invasive, and not widely available, contributing to a reality where an estimated 92% of adults with mild cognitive impairment may go undiagnosed. Blood tests offer a faster, cheaper, and more accessible first step in the diagnostic process.\n\nHowever, experts urge a clear-eyed view of their role. These tests are not meant to replace existing diagnostic tools but to supplement them. Neurologists will still rely on clinical assessments and patient history to form a complete picture.\n\nFurthermore, the tests are not without limitations. A key challenge is the \"grey zone,\" where test results are inconclusive and require further investigation. For one similar test in development, over 30% of samples fell into this ambiguous category. It is also critical that these tests are used only for individuals already showing symptoms of cognitive decline. As Dr. Ashvini Keshavan, a neurologist at University College London, notes, the presence of Alzheimer's-related proteins can increase with age and does not automatically mean they are the cause of a person's symptoms.\n\nThe arrival of these FDA-approved tests signals a new era in Alzheimer's care. With more companies working on similar technologies, the increased competition is expected to drive innovation and, most importantly, expand patient access to early answers. While not a definitive solution on their own, these blood tests provide a crucial new tool in the effort to better understand and manage Alzheimer's disease.","synthesized_article_kor":"TRANSLATION_FAILED: [GoogleGenerativeAI Error]: Error fetching from https://generativelanguage.googleapis.com/v1beta/models/gemini-2.flash:generateContent: [404 Not Found] models/gemini-2.flash is not found for API version v1beta, or is not supported for generateContent. Call ListModels to see the list of available models and their supported methods.","linkedin_en":"A Look at the New Blood Tests Approved for Alzheimer's Disease The landscape of Alzheimer's disease diagnostics is undergoing a significant transformation.  With the recent US Food and Drug Administration (FDA) approval of a second blood test designed to aid in diagnosis, clinicians and patients are gaining more accessible tools to investigate cognitive decline.  These new tests represent a major step away from invasive and costly procedures, promising earlier and more widespread assessment.  In October 2025, the FDA cleared the Elecsys pTau181 test, developed by pharmaceutical companies Roche and Eli Lilly.  This marks the second such approval in the same year, following the green light given to Fujirebio's Lumipulse test in May.  Both tests work by detecting key biological markers of Alzheimer's in the bloodstream, but they function in slightly different ways.  The pathology of Alzheimer's is characterized by the accumulation of two proteins in the brain: amyloid-Î² plaques and tangles of a protein called tau.  The new Elecsys test measures a specific modified form of tau, known as pTau181, in blood plasma.  Its primary function is to help rule out Alzheimer's as the cause of a person's cognitive impairment.  According to a clinical trial of 312 participants, the test was  9% accurate in correctly identifying individuals who did not have the disease.  This makes it a powerful initial screening tool for use in primary-care settings.  The earlier approved Lumipulse test takes a different approach.  It measures the ratio between two proteins, pTau217 and amyloid-Î².  This allows it not only to rule out Alzheimer's but also to provide a positive indication of the disease's pathology.  In its clinical trial of 499 people, the Lumipulse test showed 97% accuracy in its negative predictions and nearly 92% accuracy for its positive results when compared to follow-up diagnostic tests.  These blood-based diagnostics are being hailed as a turning point.  Previously, the only definitive ways to detect amyloid and tau buildup in living patients were through a lumbar puncture to collect cerebrospinal fluid or a positron-emission tomography (PET) scan of the brain.  These methods are expensive, invasive, and not widely available, contributing to a reality where an estimated 92% of adults with mild cognitive impairment may go undiagnosed.  Blood tests offer a faster, cheaper, and more accessible first step in the diagnostic process.  However, experts urge a clear-eyed view of their role.  These tests are not meant to replace existing diagnostic tools but to supplement them.  Neurologists will still rely on clinical assessments and patient history to form a complete picture.  Furthermore, the tests are not without limitations.  A key challenge is the \"grey zone,\" where test results are inconclusive and require further investigation.  For one similar test in development, over 30% of samples fell into this ambiguous category.  It is also critical that these tests are used only for individuals already showing symptoms of cognitive decline.  As Dr.  Ashvini Keshavan, a neurologist at University College London, notes, the presence of Alzheimer's-related proteins can increase with age and does not automatically mean they are the cause of a person's symptoms.  The arrival of these FDA-approved tests signals a new era in Alzheimer's care.  With more companies working on similar technologies, the increased competition is expected to drive innovation and, most importantly, expand patient access to early answers.  While not a definitive solution on their own, these blood tests provide a crucial new tool in the effort to better understand and manage Alzheimer's disease.","linkedin_kor":"TRANSLATION_FAILED: [GoogleGenerativeAI Error]: Error fetching from https://generativelanguage.googleapis.com/v1beta/models/gemini-2.flash:generateContent: [404 Not Found] models/gemini-2.flash is not found for API version v1beta, or is not supported for generateContent. Call ListModels to see the list of available models and their supported methods.","x_en":"(1/17) A Look at the New Blood Tests Approved for Alzheimer's Disease The landscape of Alzheimer's disease diagnostics is undergoing a significant transformation.\n\n(2/17) With the recent US Food and Drug Administration (FDA) approval of a second blood test designed to aid in diagnosis, clinicians and patients are gaining more accessible tools to investigate cognitive decline.\n\n(3/17) These new tests represent a major step away from invasive and costly procedures, promising earlier and more widespread assessment. In October 2025, the FDA cleared the Elecsys pTau181 test, developed by pharmaceutical companies Roche and Eli Lilly.\n\n(4/17) This marks the second such approval in the same year, following the green light given to Fujirebio's Lumipulse test in May. Both tests work by detecting key biological markers of Alzheimer's in the bloodstream, but they function in slightly different ways.\n\n(5/17) The pathology of Alzheimer's is characterized by the accumulation of two proteins in the brain: amyloid-Î² plaques and tangles of a protein called tau. The new Elecsys test measures a specific modified form of tau, known as pTau181, in blood plasma.\n\n(6/17) Its primary function is to help rule out Alzheimer's as the cause of a person's cognitive impairment. According to a clinical trial of 312 participants, the test was 9% accurate in correctly identifying individuals who did not have the disease.\n\n(7/17) This makes it a powerful initial screening tool for use in primary-care settings. The earlier approved Lumipulse test takes a different approach. It measures the ratio between two proteins, pTau217 and amyloid-Î².\n\n(8/17) This allows it not only to rule out Alzheimer's but also to provide a positive indication of the disease's pathology.\n\n(9/17) In its clinical trial of 499 people, the Lumipulse test showed 97% accuracy in its negative predictions and nearly 92% accuracy for its positive results when compared to follow-up diagnostic tests. These blood-based diagnostics are being hailed as a turning point.\n\n(10/17) Previously, the only definitive ways to detect amyloid and tau buildup in living patients were through a lumbar puncture to collect cerebrospinal fluid or a positron-emission tomography (PET) scan of the brain.\n\n(11/17) These methods are expensive, invasive, and not widely available, contributing to a reality where an estimated 92% of adults with mild cognitive impairment may go undiagnosed. Blood tests offer a faster, cheaper, and more accessible first step in the diagnostic process.\n\n(12/17) However, experts urge a clear-eyed view of their role. These tests are not meant to replace existing diagnostic tools but to supplement them. Neurologists will still rely on clinical assessments and patient history to form a complete picture.\n\n(13/17) Furthermore, the tests are not without limitations. A key challenge is the \"grey zone,\" where test results are inconclusive and require further investigation. For one similar test in development, over 30% of samples fell into this ambiguous category.\n\n(14/17) It is also critical that these tests are used only for individuals already showing symptoms of cognitive decline. As Dr.\n\n(15/17) Ashvini Keshavan, a neurologist at University College London, notes, the presence of Alzheimer's-related proteins can increase with age and does not automatically mean they are the cause of a person's symptoms.\n\n(16/17) The arrival of these FDA-approved tests signals a new era in Alzheimer's care. With more companies working on similar technologies, the increased competition is expected to drive innovation and, most importantly, expand patient access to early answers.\n\n(17/17) While not a definitive solution on their own, these blood tests provide a crucial new tool in the effort to better understand and manage Alzheimer's disease.","x_kor":"TRANSLATION_FAILED: [GoogleGenerativeAI Error]: Error fetching from https://generativelanguage.googleapis.com/v1beta/models/gemini-2.flash:generateContent: [404 Not Found] models/gemini-2.flash is not found for API version v1beta, or is not supported for generateContent. Call ListModels to see the list of available models and their supported methods.","facebook_en":"Here's a look at the Aspiration Bank situation: A Look at the New Blood Tests Approved for Alzheimer's Disease The landscape of Alzheimer's disease diagnostics is undergoing a significant transformation.  With the recent US Food and Drug Administration (FDA) approval of a second blood test designed to aid in diagnosis, clinicians and patients are gaining more accessible tools to investigate cognitive decline.  These new tests represent a major step away from invasive and costly procedures, promising earlier and more widespread assessment.  In October 2025, the FDA cleared the Elecsys pTau181 test, developed by pharmaceutical companies Roche and Eli Lilly.  This marks the second such approval in the same year, following the green light given to Fujirebio's Lumipulse test in May.  Both tests work by detecting key biological markers of Alzheimer's in the bloodstream, but they function in slightly different ways.  The pathology of Alzheimer's is characterized by the accumulation of two proteins in the brain: amyloid-Î² plaques and tangles of a protein called tau.  The new Elecsys test measures a specific modified form of tau, known as pTau181, in blood plasma.  Its primary function is to help rule out Alzheimer's as the cause of a person's cognitive impairment.  According to a clinical trial of 312 participants, the test was  9% accurate in correctly identifying individuals who did not have the disease.  This makes it a powerful initial screening tool for use in primary-care settings.  The earlier approved Lumipulse test takes a different approach.  It measures the ratio between two proteins, pTau217 and amyloid-Î².  This allows it not only to rule out Alzheimer's but also to provide a positive indication of the disease's pathology.  In its clinical trial of 499 people, the Lumipulse test showed 97% accuracy in its negative predictions and nearly 92% accuracy for its positive results when compared to follow-up diagnostic tests.  These blood-based diagnostics are being hailed as a turning point.  Previously, the only definitive ways to detect amyloid and tau buildup in living patients were through a lumbar puncture to collect cerebrospinal fluid or a positron-emission tomography (PET) scan of the brain.  These methods are expensive, invasive, and not widely available, contributing to a reality where an estimated 92% of adults with mild cognitive impairment may go undiagnosed.  Blood tests offer a faster, cheaper, and more accessible first step in the diagnostic process.  However, experts urge a clear-eyed view of their role.  These tests are not meant to replace existing diagnostic tools but to supplement them.  Neurologists will still rely on clinical assessments and patient history to form a complete picture.  Furthermore, the tests are not without limitations.  A key challenge is the \"grey zone,\" where test results are inconclusive and require further investigation.  For one similar test in development, over 30% of samples fell into this ambiguous category.  It is also critical that these tests are used only for individuals already showing symptoms of cognitive decline.  As Dr.  Ashvini Keshavan, a neurologist at University College London, notes, the presence of Alzheimer's-related proteins can increase with age and does not automatically mean they are the cause of a person's symptoms.  The arrival of these FDA-approved tests signals a new era in Alzheimer's care.  With more companies working on similar technologies, the increased competition is expected to drive innovation and, most importantly, expand patient access to early answers.  While not a definitive solution on their own, these blood tests provide a crucial new tool in the effort to better understand and manage Alzheimer's disease. What are your thoughts on this? Let us know in the comments! ğŸ‘‡","facebook_kor":"TRANSLATION_FAILED: [GoogleGenerativeAI Error]: Error fetching from https://generativelanguage.googleapis.com/v1beta/models/gemini-2.flash:generateContent: [404 Not Found] models/gemini-2.flash is not found for API version v1beta, or is not supported for generateContent. Call ListModels to see the list of available models and their supported methods.","threads_en":"(1/17) A Look at the New Blood Tests Approved for Alzheimer's Disease The landscape of Alzheimer's disease diagnostics is undergoing a significant transformation.\n\n(2/17) With the recent US Food and Drug Administration (FDA) approval of a second blood test designed to aid in diagnosis, clinicians and patients are gaining more accessible tools to investigate cognitive decline.\n\n(3/17) These new tests represent a major step away from invasive and costly procedures, promising earlier and more widespread assessment. In October 2025, the FDA cleared the Elecsys pTau181 test, developed by pharmaceutical companies Roche and Eli Lilly.\n\n(4/17) This marks the second such approval in the same year, following the green light given to Fujirebio's Lumipulse test in May. Both tests work by detecting key biological markers of Alzheimer's in the bloodstream, but they function in slightly different ways.\n\n(5/17) The pathology of Alzheimer's is characterized by the accumulation of two proteins in the brain: amyloid-Î² plaques and tangles of a protein called tau. The new Elecsys test measures a specific modified form of tau, known as pTau181, in blood plasma.\n\n(6/17) Its primary function is to help rule out Alzheimer's as the cause of a person's cognitive impairment. According to a clinical trial of 312 participants, the test was 9% accurate in correctly identifying individuals who did not have the disease.\n\n(7/17) This makes it a powerful initial screening tool for use in primary-care settings. The earlier approved Lumipulse test takes a different approach. It measures the ratio between two proteins, pTau217 and amyloid-Î².\n\n(8/17) This allows it not only to rule out Alzheimer's but also to provide a positive indication of the disease's pathology.\n\n(9/17) In its clinical trial of 499 people, the Lumipulse test showed 97% accuracy in its negative predictions and nearly 92% accuracy for its positive results when compared to follow-up diagnostic tests. These blood-based diagnostics are being hailed as a turning point.\n\n(10/17) Previously, the only definitive ways to detect amyloid and tau buildup in living patients were through a lumbar puncture to collect cerebrospinal fluid or a positron-emission tomography (PET) scan of the brain.\n\n(11/17) These methods are expensive, invasive, and not widely available, contributing to a reality where an estimated 92% of adults with mild cognitive impairment may go undiagnosed. Blood tests offer a faster, cheaper, and more accessible first step in the diagnostic process.\n\n(12/17) However, experts urge a clear-eyed view of their role. These tests are not meant to replace existing diagnostic tools but to supplement them. Neurologists will still rely on clinical assessments and patient history to form a complete picture.\n\n(13/17) Furthermore, the tests are not without limitations. A key challenge is the \"grey zone,\" where test results are inconclusive and require further investigation. For one similar test in development, over 30% of samples fell into this ambiguous category.\n\n(14/17) It is also critical that these tests are used only for individuals already showing symptoms of cognitive decline. As Dr.\n\n(15/17) Ashvini Keshavan, a neurologist at University College London, notes, the presence of Alzheimer's-related proteins can increase with age and does not automatically mean they are the cause of a person's symptoms.\n\n(16/17) The arrival of these FDA-approved tests signals a new era in Alzheimer's care. With more companies working on similar technologies, the increased competition is expected to drive innovation and, most importantly, expand patient access to early answers.\n\n(17/17) While not a definitive solution on their own, these blood tests provide a crucial new tool in the effort to better understand and manage Alzheimer's disease.","threads_kor":"TRANSLATION_FAILED: [GoogleGenerativeAI Error]: Error fetching from https://generativelanguage.googleapis.com/v1beta/models/gemini-2.flash:generateContent: [404 Not Found] models/gemini-2.flash is not found for API version v1beta, or is not supported for generateContent. Call ListModels to see the list of available models and their supported methods.","editor_profile":"simple","linkedin_edited_kor":"**ì´ì œ ê°„ë‹¨í•œ í˜ˆì•¡ ê²€ì‚¬ë¡œ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì„ ì¡°ê¸°ì— ë°œê²¬í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤**\n\nìµœê·¼ ë¯¸êµ­ ì‹í’ˆì˜ì•½êµ­(FDA)ì´ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì„ ì§„ë‹¨í•˜ëŠ” ìƒˆë¡œìš´ í˜ˆì•¡ ê²€ì‚¬ë¥¼ ìŠ¹ì¸í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì•Œì¸ í•˜ì´ë¨¸ ì§„ë‹¨ ë°©ì‹ê³¼ ì¹˜ë£Œì— ìˆì–´ ë§¤ìš° ì¤‘ìš”í•œ ë³€í™”ì´ë©°, í™˜ìë“¤ì—ê²Œ ìƒˆë¡œìš´ í¬ë§ì„ ì£¼ê³  ìˆìŠµë‹ˆë‹¤.\n\n**ë¬´ì—‡ì´ ì–´ë–»ê²Œ ë‹¬ë¼ì§€ë‚˜ìš”?**\n\nì´ì „ê¹Œì§€ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì„ ì§„ë‹¨í•˜ë ¤ë©´ ë¹„ì‹¼ ë‡Œ ì˜ìƒ ì´¬ì˜(PET ìŠ¤ìº”)ì´ë‚˜ ê³ í†µìŠ¤ëŸ¬ìš´ ì²™ìˆ˜ì•¡ ê²€ì‚¬ë¥¼ ë°›ì•„ì•¼ í–ˆìŠµë‹ˆë‹¤. ì´ ë•Œë¬¸ì— ë§ì€ ì‚¬ëŒì´ ê²€ì‚¬ë¥¼ êº¼ë ¸ê³ , ì¦ìƒì´ ì‹¬í•´ì§€ê¸° ì „ê¹Œì§€ëŠ” ì§„ë‹¨ì„ ë°›ì§€ ëª»í•˜ëŠ” ê²½ìš°ê°€ ëŒ€ë¶€ë¶„ì´ì—ˆìŠµë‹ˆë‹¤.\n\ní•˜ì§€ë§Œ ì´ì œëŠ” ë™ë„¤ ë³‘ì›ì—ì„œë„ ê°„ë‹¨í•œ í”¼ê²€ì‚¬ë§Œìœ¼ë¡œ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì˜ ì§•í›„ë¥¼ í™•ì¸í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ë•ë¶„ì— í›¨ì”¬ ë” ë§ì€ ì‚¬ëŒì´ ì €ë ´í•˜ê³  í¸ë¦¬í•˜ê²Œ ì¡°ê¸° ê²€ì‚¬ë¥¼ ë°›ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì œë•Œ ì§„ë‹¨ë°›ì§€ ëª»í•´ ì¹˜ë£Œ ì‹œê¸°ë¥¼ ë†“ì¹˜ëŠ” ë¬¸ì œë¥¼ í•´ê²°í•˜ëŠ” ë° í° ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤.\n\n**ì£¼ìš” í˜ˆì•¡ ê²€ì‚¬ë“¤**\n\ní˜„ì¬ FDA ìŠ¹ì¸ì„ ë°›ì€ ëŒ€í‘œì ì¸ ë‘ ê°€ì§€ ê²€ì‚¬ê°€ ìˆìŠµë‹ˆë‹¤.\n\n1.  **ë¡œìŠˆ & ì¼ë¼ì´ ë¦´ë¦¬ ì‚¬ì˜ ê²€ì‚¬:** ì´ ê²€ì‚¬ëŠ” ì•Œì¸ í•˜ì´ë¨¸ë³‘ì´ **ì•„ë‹** í™•ë¥ ì„ ë§¤ìš° ë†’ì€ ì •í™•ë„ë¡œ ì•Œë ¤ì¤ë‹ˆë‹¤. ë§Œì•½ ì´ ê²€ì‚¬ì—ì„œ 'ìŒì„±'ì´ ë‚˜ì˜¤ë©´, í™˜ìëŠ” ë” ë³µì¡í•˜ê³  ë¹„ì‹¼ ì¶”ê°€ ê²€ì‚¬ë¥¼ ë°›ì§€ ì•Šì•„ë„ ëœë‹¤ëŠ” ì•ˆë„ê°ì„ ì–»ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í™˜ìì˜ ë¶€ë‹´ì„ ëœì–´ì£¼ê³  ì˜ë£Œ ë¹„ìš©ì„ ì ˆê°í•˜ëŠ” íš¨ê³¼ê°€ ìˆìŠµë‹ˆë‹¤. ë˜í•œ, ì œì•½ì‚¬ì¸ ì¼ë¼ì´ ë¦´ë¦¬ëŠ” ì´ ê²€ì‚¬ë¥¼ í†µí•´ ìì‚¬ì˜ ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œê°€ í•„ìš”í•œ í™˜ìë¥¼ ë” ì‰½ê²Œ ì°¾ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n\n2.  **í›„ì§€ë ˆë¹„ì˜¤ ì‚¬ì˜ ê²€ì‚¬:** ì´ ê²€ì‚¬ëŠ” ì•Œì¸ í•˜ì´ë¨¸ë³‘ì´ ì•„ë‹ˆë¼ëŠ” ê²ƒì„ ì•Œë ¤ì¤„ ë¿ë§Œ ì•„ë‹ˆë¼, ì•Œì¸ í•˜ì´ë¨¸ë³‘ì¼ ê°€ëŠ¥ì„±ì´ ë†’ë‹¤ëŠ” ì ë„ ê½¤ ì •í™•í•˜ê²Œ **í™•ì¸**í•´ì£¼ëŠ” ì¥ì ì´ ìˆìŠµë‹ˆë‹¤. ì´ì²˜ëŸ¼ ë‘ ê°€ì§€ ê¸°ëŠ¥ì„ ëª¨ë‘ ê°–ì¶”ê³  ìˆì–´, ì˜ì‚¬ë“¤ì´ ì´ˆê¸° ì§„ë‹¨ì— ë” ì„ í˜¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n\n**ì´ê²ƒì´ ì™œ ì¤‘ìš”í•œê°€ìš”?**\n\nì´ í˜ˆì•¡ ê²€ì‚¬ë“¤ì´ ê°€ì ¸ì˜¬ ê°€ì¥ í° ë³€í™”ëŠ” ë°”ë¡œ **ì¹˜ë£Œì™€ì˜ ì—°ê³„**ì…ë‹ˆë‹¤.\n\n*   **íš¨ê³¼ì ì¸ ì¹˜ë£Œì˜ ë¬¸ì„ ì—½ë‹ˆë‹¤:** ì§€ê¸ˆê¹Œì§€ ê°œë°œëœ ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œë“¤ì€ ë³‘ì´ ë§ì´ ì§„í–‰ë˜ê¸° ì „, ì´ˆê¸°ì— íˆ¬ì—¬í•´ì•¼ íš¨ê³¼ê°€ ê°€ì¥ ì¢‹ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ í™˜ìë¥¼ ì¡°ê¸°ì— ì°¾ì•„ë‚´ëŠ” ê²ƒì´ ì–´ë ¤ì›Œ ì•½ì˜ íš¨ê³¼ë¥¼ ì œëŒ€ë¡œ ë³´ì§€ ëª»í•˜ëŠ” ê²½ìš°ê°€ ë§ì•˜ìŠµë‹ˆë‹¤. ì´ í˜ˆì•¡ ê²€ì‚¬ëŠ” ê·¸ ë¬¸ì œë¥¼ í•´ê²°í•´ ì¤ë‹ˆë‹¤. ë” ë§ì€ í™˜ìê°€ ì¡°ê¸°ì— ì§„ë‹¨ë°›ê³  ì œë•Œ ì¹˜ë£Œë¥¼ ì‹œì‘í•  ìˆ˜ ìˆê²Œ ë˜ì–´, ì¹˜ë£Œì œì˜ íš¨ê³¼ë¥¼ ê·¹ëŒ€í™”í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n\n*   **ë¯¸ë˜ì˜ í¬ë§:** ì´ ê²€ì‚¬ë“¤ì€ ì‹œì‘ì— ë¶ˆê³¼í•©ë‹ˆë‹¤. ì•ìœ¼ë¡œ ê³¼í•™ìë“¤ì€ ì •í™•ë„ë¥¼ ë”ìš± ë†’ì´ê³ , ì¦ìƒì´ ë‚˜íƒ€ë‚˜ê¸° ëª‡ ë…„ ì „ì— ë¯¸ë¦¬ ìœ„í—˜ì„ ì˜ˆì¸¡í•  ìˆ˜ ìˆëŠ” ë” ë°œì „ëœ ê²€ì‚¬ë¥¼ ê°œë°œí•˜ê¸° ìœ„í•´ ë…¸ë ¥í•  ê²ƒì…ë‹ˆë‹¤.\n\nê²°ë¡ ì ìœ¼ë¡œ, ì´ ìƒˆë¡œìš´ í˜ˆì•¡ ê²€ì‚¬ëŠ” ë‹¨ìˆœíˆ ì§„ë‹¨ ê¸°ìˆ ì˜ ë°œì „ì´ ì•„ë‹™ë‹ˆë‹¤. ì•Œì¸ í•˜ì´ë¨¸ë³‘ìœ¼ë¡œ ê³ í†µë°›ëŠ” ìˆ˜ë§ì€ í™˜ìì™€ ê°€ì¡±ì—ê²Œ ì¡°ê¸° ì§„ë‹¨ê³¼ íš¨ê³¼ì ì¸ ì¹˜ë£Œì˜ ê¸¸ì„ ì—´ì–´ì£¼ëŠ” ì¤‘ìš”í•œ ì—´ì‡ ì…ë‹ˆë‹¤.","x_edited_kor":"## ì•Œì¸ í•˜ì´ë¨¸ë³‘, ì´ì œ í”¼ í•œ ë°©ìš¸ë¡œ ê²€ì‚¬í•©ë‹ˆë‹¤: ë¬´ì—‡ì´ ë‹¬ë¼ì§ˆê¹Œìš”?\n\nìµœê·¼ ë¯¸êµ­ ì‹í’ˆì˜ì•½êµ­(FDA)ì´ ê°„ë‹¨í•œ í˜ˆì•¡ ê²€ì‚¬ë¡œ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì„ ì§„ë‹¨í•˜ëŠ” ê¸°ìˆ ì„ ìŠ¹ì¸í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì•Œì¸ í•˜ì´ë¨¸ ì§„ë‹¨ê³¼ ì¹˜ë£Œì— ìˆì–´ ë§¤ìš° ì¤‘ìš”í•œ ë³€í™”ë¡œ, ì•ìœ¼ë¡œ ë§ì€ ê²ƒë“¤ì´ ë‹¬ë¼ì§ˆ ê²ƒì…ë‹ˆë‹¤.\n\n### ì™œ ì´ê²ƒì´ 'í˜ì‹ 'ì ì¸ ë³€í™”ì¼ê¹Œìš”?\n\n*   **ê¸°ì¡´ ë°©ì‹:** ì´ì „ì—ëŠ” ì•Œì¸ í•˜ì´ë¨¸ë³‘ì„ ì§„ë‹¨í•˜ë ¤ë©´ ë¹„ì‹¼ ë‡Œ ì˜ìƒ ì´¬ì˜(PET ìŠ¤ìº”)ì„ í•˜ê±°ë‚˜, ì²™ìˆ˜ì•¡ì„ ë½‘ëŠ” ë¶ˆí¸í•œ ê²€ì‚¬(ìš”ì¶” ì²œì)ë¥¼ ë°›ì•„ì•¼ í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë§ì€ ì‚¬ëŒë“¤ì´ ê²€ì‚¬ë¥¼ êº¼ë¦¬ê±°ë‚˜ ë¯¸ë£¨ê³¤ í–ˆìŠµë‹ˆë‹¤.\n\n*   **ìƒˆë¡œìš´ ë°©ì‹:** ì´ì œëŠ” ê°€ê¹Œìš´ ë³‘ì›ì—ì„œ ê°„ë‹¨íˆ í”¼ë¥¼ ë½‘ëŠ” ê²ƒë§Œìœ¼ë¡œ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì˜ ê°€ëŠ¥ì„±ì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n\n*   **ê²°ê³¼:** ë” ë§ì€ ì‚¬ëŒë“¤ì´ ë” ë¹ ë¥´ê³  ì €ë ´í•˜ê²Œ ê²€ì‚¬ë¥¼ ë°›ì„ ìˆ˜ ìˆê²Œ ë˜ì–´, ë³‘ì„ ì¡°ê¸°ì— ë°œê²¬í•˜ê³  ì¹˜ë£Œë¥¼ ì‹œì‘í•  ê¸°íšŒê°€ í¬ê²Œ ëŠ˜ì–´ë‚©ë‹ˆë‹¤. ì´ì „ì—ëŠ” ì§„ë‹¨ì¡°ì°¨ ë°›ì§€ ëª»í–ˆë˜ ìˆ˜ë§ì€ ì´ˆê¸° ë‹¨ê³„ì˜ í™˜ìë“¤ì„ ì°¾ì•„ë‚¼ ìˆ˜ ìˆê²Œ ëœ ê²ƒì…ë‹ˆë‹¤.\n\n### ìƒˆë¡œìš´ í˜ˆì•¡ ê²€ì‚¬ë¥¼ ë§Œë“œëŠ” ì£¼ìš” íšŒì‚¬ë“¤ì€ ì–´ë””ì¼ê¹Œìš”?\n\ní˜„ì¬ FDAì˜ ìŠ¹ì¸ì„ ë°›ì€ ë‘ ê°€ì§€ ì£¼ìš” ê²€ì‚¬ê°€ ìˆìŠµë‹ˆë‹¤.\n\n1.  **ë¡œìŠˆ & ì¼ë¼ì´ ë¦´ë¦¬ç¤¾ì˜ ê²€ì‚¬:** ì´ ê²€ì‚¬ì˜ ê°€ì¥ í° ì¥ì ì€ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì´ â€˜ì•„ë‹â€™ í™•ë¥ ì„ ë§¤ìš° ë†’ì€ ì •í™•ë„ë¡œ ì•Œë ¤ì¤€ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ ê²€ì‚¬ì—ì„œ ìŒì„±ì´ ë‚˜ì˜¤ë©´, ë§ì€ í™˜ìë“¤ì´ ë” ë¹„ì‹¸ê³  ë³µì¡í•œ ì¶”ê°€ ê²€ì‚¬ë¥¼ ë°›ì„ í•„ìš”ê°€ ì—†ì–´ì§‘ë‹ˆë‹¤. ì´ëŠ” í™˜ìì™€ ì˜ë£Œ ì‹œìŠ¤í…œ ëª¨ë‘ì˜ ë¶€ë‹´ì„ ëœì–´ì£¼ëŠ” ì¤‘ìš”í•œ ì—­í• ì„ í•©ë‹ˆë‹¤.\n\n2.  **í›„ì§€ë ˆë¹„ì˜¤ç¤¾ì˜ ê²€ì‚¬:** ì´ ê²€ì‚¬ëŠ” ë³‘ì´ â€˜ì•„ë‹ˆë‹¤â€™ë¼ê³  ì•Œë ¤ì£¼ëŠ” ê¸°ëŠ¥ë¿ë§Œ ì•„ë‹ˆë¼, ë³‘ì´ â€˜ë§ì„â€™ ê°€ëŠ¥ì„±ì´ ë†’ë‹¤ëŠ” ê²ƒë„ ê½¤ ì •í™•í•˜ê²Œ ì•Œë ¤ì£¼ëŠ” ê°•ì ì„ ê°€ì§‘ë‹ˆë‹¤. ì˜ì‚¬ë“¤ì´ ì²« ê²€ì‚¬ì—ì„œ ë” í™•ì‹¤í•œ ì •ë³´ë¥¼ ì–»ê³  ì‹¶ì„ ë•Œ ì„ í˜¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n\n**í•µì‹¬ì€ â€˜ì •í™•ë„â€™ì…ë‹ˆë‹¤.** ì–´ë–¤ ê²€ì‚¬ë“¤ì€ ê²°ê³¼ê°€ ì• ë§¤í•˜ê²Œ ë‚˜ì˜¤ëŠ” â€˜íšŒìƒ‰ ì§€ëŒ€â€™ê°€ ìˆì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œëŠ” ê°€ì¥ ì •í™•í•˜ê³  ëª…í™•í•œ ê²°ê³¼ë¥¼ ì œê³µí•˜ëŠ” ê²€ì‚¬ê°€ ì‹œì¥ì„ ì£¼ë„í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.\n\n### ì´ê²ƒì´ í™˜ìì™€ ì¹˜ë£Œì— ë¯¸ì¹˜ëŠ” ê°€ì¥ í° ì˜í–¥ì€ ë¬´ì—‡ì¼ê¹Œìš”?\n\nê°€ì¥ ì¤‘ìš”í•œ ì ì€ ì´ í˜ˆì•¡ ê²€ì‚¬ê°€ ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œì™€ ë§Œë‚¬ì„ ë•Œ ìƒê¸°ëŠ” ì—„ì²­ë‚œ ì‹œë„ˆì§€ì…ë‹ˆë‹¤.\n\n*   **ì¹˜ë£Œì˜ ë¬¸ì„ ì—´ë‹¤:** ì§€ê¸ˆê¹Œì§€ ì•Œì¸ í•˜ì´ë¨¸ ì‹ ì•½ì´ ì„±ê³µí•˜ê¸° ì–´ë ¤ì› ë˜ ê°€ì¥ í° ì´ìœ  ì¤‘ í•˜ë‚˜ëŠ”, ì•½ì´ íš¨ê³¼ë¥¼ ë³¼ ìˆ˜ ìˆì„ ë§Œí¼ â€˜ì¼ì°â€™ ì ì ˆí•œ í™˜ìë¥¼ ì°¾ê¸° ì–´ë ¤ì› ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ í˜ˆì•¡ ê²€ì‚¬ê°€ ë°”ë¡œ ê·¸ ë¬¸ì œë¥¼ í•´ê²°í•´ ì¤ë‹ˆë‹¤.\n\n*   **ì œì•½ íšŒì‚¬ì— ë¯¸ì¹˜ëŠ” ì˜í–¥:** í˜ˆì•¡ ê²€ì‚¬ë¥¼ í†µí•´ ì¡°ê¸°ì— ì§„ë‹¨ë°›ì€ í™˜ìë“¤ì´ í¬ê²Œ ëŠ˜ì–´ë‚˜ë©´ì„œ, ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œë¥¼ ê°œë°œí•˜ëŠ” íšŒì‚¬ë“¤(ì˜ˆ: ì¼ë¼ì´ ë¦´ë¦¬, ë°”ì´ì˜¤ì   ë“±)ì€ ë” ë§ì€ í™˜ìì—ê²Œ ì•½ì„ ê³µê¸‰í•  ê¸°íšŒë¥¼ ì–»ê²Œ ë©ë‹ˆë‹¤. ì¦‰, ì§„ë‹¨ ê¸°ìˆ ì˜ ë°œì „ì´ ì‹ ì•½ì˜ ì„±ê³µì„ ì´ë„ëŠ” ê²ƒì…ë‹ˆë‹¤.\n\n*   **ë¯¸ë˜ ì „ë§:** ì´ê²ƒì€ ì‹œì‘ì— ë¶ˆê³¼í•©ë‹ˆë‹¤. ì•ìœ¼ë¡œëŠ” ì •í™•ë„ë¥¼ ë”ìš± ë†’ì´ê³ , ì¦ìƒì´ ë‚˜íƒ€ë‚˜ê¸° ëª‡ ë…„ ì „ì— ë°œë³‘ ìœ„í—˜ê¹Œì§€ ì˜ˆì¸¡í•˜ëŠ” ë” ë°œì „ëœ ê²€ì‚¬ë“¤ì´ ë“±ì¥í•  ê²ƒì…ë‹ˆë‹¤.\n\n### ê²°ë¡ \n\nì´ë²ˆ ì•Œì¸ í•˜ì´ë¨¸ í˜ˆì•¡ ê²€ì‚¬ì˜ ìŠ¹ì¸ì€ ë‹¨ìˆœíˆ ë” ë‚˜ì€ ì§„ë‹¨ ë„êµ¬ê°€ ë‚˜ì˜¨ ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì˜ ìƒˆë¡œìš´ ì‹œëŒ€ë¥¼ ì—¬ëŠ” ì—´ì‡ ì™€ë„ ê°™ìŠµë‹ˆë‹¤. ì´ì œ ë” ë§ì€ ì‚¬ëŒë“¤ì´ ì¡°ê¸°ì— ë³‘ì„ ë°œê²¬í•˜ê³ , ì œì•½ íšŒì‚¬ë“¤ì€ ë” íš¨ê³¼ì ìœ¼ë¡œ ì¹˜ë£Œì œë¥¼ ê°œë°œí•˜ê³  ê³µê¸‰í•  ìˆ˜ ìˆê²Œ ë  ê²ƒì…ë‹ˆë‹¤.","facebook_edited_kor":"**ì•Œì¸ í•˜ì´ë¨¸ë³‘, ì´ì œ ê°„ë‹¨í•œ í”¼ê²€ì‚¬ë¡œ ì§„ë‹¨ ê°€ëŠ¥í•´ì§„ë‹¤**\n\nì§€ê¸ˆê¹Œì§€ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì„ ì§„ë‹¨í•˜ëŠ” ê²ƒì€ ë§¤ìš° ë³µì¡í•˜ê³  ì–´ë ¤ìš´ ê³¼ì •ì´ì—ˆìŠµë‹ˆë‹¤. ë‡Œë¥¼ ì§ì ‘ ì´¬ì˜í•˜ëŠ” ë¹„ì‹¼ PET ìŠ¤ìº”ì„ ë°›ê±°ë‚˜, ì²™ì¶”ì—ì„œ ì•¡ì²´ë¥¼ ë½‘ì•„ë‚´ëŠ” ê³ í†µìŠ¤ëŸ¬ìš´ ê²€ì‚¬ë¥¼ ê±°ì³ì•¼ í–ˆìŠµë‹ˆë‹¤. ì´ ë•Œë¬¸ì— ë§ì€ ì‚¬ëŒë“¤ì´ ì§„ë‹¨ì„ ë§ì„¤ì´ê±°ë‚˜ ë„ˆë¬´ ëŠ¦ê²Œ ë³‘ì„ ë°œê²¬í•˜ê³¤ í–ˆìŠµë‹ˆë‹¤.\n\ní•˜ì§€ë§Œ ìµœê·¼ ë¯¸êµ­ ì‹í’ˆì˜ì•½êµ­(FDA)ì´ ìƒˆë¡œìš´ í˜ˆì•¡ ê²€ì‚¬ë¥¼ ìŠ¹ì¸í•˜ë©´ì„œ ëª¨ë“  ê²ƒì´ ë°”ë€Œì—ˆìŠµë‹ˆë‹¤. ì´ì œ ê°€ê¹Œìš´ ë³‘ì›ì—ì„œ ê°„ë‹¨í•œ í”¼ê²€ì‚¬ë§Œìœ¼ë¡œ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì˜ ê°€ëŠ¥ì„±ì„ ì¡°ê¸°ì— í™•ì¸í•  ìˆ˜ ìˆê²Œ ëœ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì§„ë‹¨ ë°©ì‹ì˜ í˜ì‹ ì¼ ë¿ë§Œ ì•„ë‹ˆë¼, ê´€ë ¨ ì‚°ì—… ì „ì²´ì— í° ë³€í™”ë¥¼ ê°€ì ¸ì˜¬ ì¤‘ìš”í•œ ì‚¬ê±´ì…ë‹ˆë‹¤.\n\n**ë¬´ì—‡ì´, ì–´ë–»ê²Œ ë‹¬ë¼ì§€ë‚˜?**\n\nì´ ê°„ë‹¨í•œ í˜ˆì•¡ ê²€ì‚¬ í•˜ë‚˜ê°€ ì‹œì¥ì˜ íŒë„ë¥¼ ë°”ê¾¸ê³  ìˆìŠµë‹ˆë‹¤.\n\n*   **ì§„ë‹¨ ì‹œì¥ì˜ í™•ëŒ€:** ì´ì „ì—ëŠ” ì†Œìˆ˜ì˜ ì „ë¬¸ ë³‘ì›ì—ì„œë§Œ ê°€ëŠ¥í–ˆë˜ ì•Œì¸ í•˜ì´ë¨¸ ê²€ì‚¬ê°€ ì´ì œëŠ” ë™ë„¤ ë³‘ì›ì—ì„œë„ ê°€ëŠ¥í•´ì§‘ë‹ˆë‹¤. ë•ë¶„ì— ë” ë§ì€ ì‚¬ëŒë“¤ì´ ì¡°ê¸°ì— ê²€ì‚¬ë¥¼ ë°›ê³  ì§„ë‹¨ë°›ì„ ìˆ˜ ìˆê²Œ ë˜ì–´, ê±°ëŒ€í•œ ìƒˆë¡œìš´ ì‹œì¥ì´ ì—´ë¦¬ê²Œ ë©ë‹ˆë‹¤.\n*   **ê¸°ì¡´ ê²€ì‚¬ ë°©ì‹ì˜ ë³€í™”:** í˜ˆì•¡ ê²€ì‚¬ê°€ 1ì°¨ì ì¸ ì„ ë³„ ë„êµ¬ë¡œ ìë¦¬ ì¡ìœ¼ë©´, ë¹„ì‹¸ê³  ë³µì¡í–ˆë˜ PET ìŠ¤ìº” ê°™ì€ ê¸°ì¡´ ê²€ì‚¬ëŠ” ê¼­ í•„ìš”í•œ ê²½ìš°ì—ë§Œ ì‚¬ìš©í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.\n\n**ì£¼ëª©í•´ì•¼ í•  ê¸°ì—…ë“¤ì€?**\n\ní˜„ì¬ FDAì˜ ìŠ¹ì¸ì„ ë°›ì€ ë‘ ê°€ì§€ ì£¼ìš” ê²€ì‚¬ê°€ ì‹œì¥ì„ ì´ëŒê³  ìˆìŠµë‹ˆë‹¤.\n\n1.  **ë¡œìŠˆ & ì¼ë¼ì´ ë¦´ë¦¬ì˜ ê²€ì‚¬:** ì´ ê²€ì‚¬ëŠ” ì•Œì¸ í•˜ì´ë¨¸ë³‘ì´ 'ì•„ë‹' í™•ë¥ ì„ 99%ì˜ ë§¤ìš° ë†’ì€ ì •í™•ë„ë¡œ ì•Œë ¤ì¤ë‹ˆë‹¤. ì¦‰, ê²€ì‚¬ ê²°ê³¼ê°€ ì •ìƒì´ë©´ \"ì•Œì¸ í•˜ì´ë¨¸ ê±±ì •ì€ ì•ˆ í•˜ì…”ë„ ë©ë‹ˆë‹¤\"ë¼ê³  ë§í•  ìˆ˜ ìˆì–´, ë¶ˆí•„ìš”í•œ ì¶”ê°€ ê²€ì‚¬ë¥¼ ë§‰ì•„ ì˜ë£Œ ë¹„ìš©ì„ ì¤„ì—¬ì£¼ëŠ” íš¨ê³¼ê°€ í½ë‹ˆë‹¤. íŠ¹íˆ ì œì•½ì‚¬ 'ì¼ë¼ì´ ë¦´ë¦¬'ì—ê²ŒëŠ” ìì‚¬ì˜ ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œê°€ í•„ìš”í•œ í™˜ìë“¤ì„ ë” ì‰½ê²Œ ì°¾ì•„ë‚´ëŠ” ì¤‘ìš”í•œ ìˆ˜ë‹¨ì´ ë©ë‹ˆë‹¤.\n\n2.  **í›„ì§€ë ˆë¹„ì˜¤ì˜ ê²€ì‚¬:** ì´ ê²€ì‚¬ëŠ” ë³‘ì´ 'ì•„ë‹ˆë‹¤'ë¼ëŠ” ê²ƒì„ ì•Œë ¤ì¤„ ë¿ë§Œ ì•„ë‹ˆë¼, 'ë§ë‹¤'ë¼ëŠ” ê²ƒë„ ë†’ì€ ì •í™•ë„ë¡œ íŒë³„í•  ìˆ˜ ìˆëŠ” ì ì¬ë ¥ì„ ê°€ì¡ŒìŠµë‹ˆë‹¤. ì˜ì‚¬ ì…ì¥ì—ì„œëŠ” ë” ëª…í™•í•œ ì´ˆê¸° ì •ë³´ë¥¼ ì–»ì„ ìˆ˜ ìˆì–´ ì„ í˜¸ë„ê°€ ë†’ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n\në¬¼ë¡  ì•„ì§ í•´ê²°í•  ê³¼ì œë„ ìˆìŠµë‹ˆë‹¤. ë•Œë¡œëŠ” ê²€ì‚¬ ê²°ê³¼ê°€ 'ë¶ˆí™•ì‹¤'í•˜ê²Œ ë‚˜ì˜¤ëŠ” ê²½ìš°ê°€ ìˆëŠ”ë°, ì•ìœ¼ë¡œ ì–´ë–¤ íšŒì‚¬ê°€ ì´ ë¶ˆí™•ì‹¤ì„±ì„ ì¤„ì´ê³  ê°€ì¥ ì •í™•í•œ ê²°ê³¼ë¥¼ ì œê³µí•˜ëŠëƒê°€ ì„±ê³µì˜ ê´€ê±´ì´ ë  ê²ƒì…ë‹ˆë‹¤.\n\n**ì´ê²ƒì´ ì™œ íˆ¬ììì—ê²Œ ì¤‘ìš”í•œê°€?**\n\nì´ í˜ˆì•¡ ê²€ì‚¬ì˜ ë“±ì¥ì€ íŠ¹íˆ ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œë¥¼ ê°œë°œí•˜ëŠ” ì œì•½ íšŒì‚¬ë“¤ì—ê²Œ ì—„ì²­ë‚œ ê¸°íšŒë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤.\n\n*   **ì œì•½ ì‚°ì—…ì˜ ìƒˆë¡œìš´ ì„±ì¥ ë™ë ¥:** ê·¸ë™ì•ˆ ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œëŠ” ì•½íš¨ê°€ ê°€ì¥ ì¢‹ì€ ì´ˆê¸°ì— í™˜ìë¥¼ ì°¾ì•„ë‚´ê¸°ê°€ ë§¤ìš° ì–´ë ¤ì› ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ì œ í˜ˆì•¡ ê²€ì‚¬ë¡œ ì¡°ê¸° ì§„ë‹¨ì´ ê°€ëŠ¥í•´ì§€ë©´ì„œ ì´ ê°€ì¥ í° ê±¸ë¦¼ëŒì´ ì‚¬ë¼ì¡ŒìŠµë‹ˆë‹¤. 'ì¼ë¼ì´ ë¦´ë¦¬'ë‚˜ 'ë°”ì´ì˜¤ì  'ì²˜ëŸ¼ ì•Œì¸ í•˜ì´ë¨¸ ì‹ ì•½ì„ ê°€ì§„ íšŒì‚¬ë“¤ì€ ì´ì œ ì¹˜ë£Œê°€ í•„ìš”í•œ í™˜ìë“¤ì„ í›¨ì”¬ ë” ë§ì´, ê·¸ë¦¬ê³  ë” ì¼ì° ì°¾ì„ ìˆ˜ ìˆê²Œ ë˜ì–´ ì•½ë¬¼ íŒë§¤ê°€ í¬ê²Œ ëŠ˜ì–´ë‚  ê²ƒì…ë‹ˆë‹¤. ì¦‰, í˜ˆì•¡ ê²€ì‚¬ ì‚¬ìš©ëŸ‰ì€ ê³§ ì¹˜ë£Œì œ ì‹œì¥ì˜ ì„±ì¥ì„ ì˜ˆê³ í•˜ëŠ” ì‹ í˜¸íƒ„ê³¼ ê°™ìŠµë‹ˆë‹¤.\n\n*   **ì§„ë‹¨ íšŒì‚¬ë“¤ì˜ ì§ì ‘ì ì¸ ìˆ˜ìµ:** ë‹¹ì—°íˆ ì´ í˜ì‹ ì ì¸ ê²€ì‚¬ë¥¼ ê°œë°œí•œ 'ë¡œìŠˆ'ì™€ ê°™ì€ íšŒì‚¬ë“¤ë„ í° ìˆ˜ìµì„ ì–»ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.\n\n**ê²°ë¡ : ì‹œì¥ì˜ íŒë„ë¥¼ ë°”ê¾¸ëŠ” ì—´ì‡ **\n\nìƒˆë¡œìš´ ì•Œì¸ í•˜ì´ë¨¸ í˜ˆì•¡ ê²€ì‚¬ëŠ” ë‹¨ìˆœíˆ í¸ë¦¬í•œ ì§„ë‹¨ ë„êµ¬ê°€ ì•„ë‹™ë‹ˆë‹¤. ì´ê²ƒì€ ê·¸ë™ì•ˆ ë‹«í˜€ ìˆë˜ ê±°ëŒ€í•œ ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œ ì‹œì¥ì˜ ë¬¸ì„ í™œì§ ì—¬ëŠ” 'ì—´ì‡ 'ì™€ ê°™ìŠµë‹ˆë‹¤. ë‹¨ê¸°ì ìœ¼ë¡œëŠ” ê²€ì‚¬ë¥¼ ë§Œë“œëŠ” íšŒì‚¬ë“¤ì´ ì£¼ëª©ë°›ê² ì§€ë§Œ, ì¥ê¸°ì ìœ¼ë¡œ ê°€ì¥ í° í˜œíƒì€ ì´ ê²€ì‚¬ë¥¼ í†µí•´ ìˆ˜ë§ì€ í™˜ìë¥¼ í™•ë³´í•˜ê²Œ ë  ì‹ ì•½ ê°œë°œ ì œì•½ì‚¬ë“¤ì—ê²Œ ëŒì•„ê°ˆ ê²ƒì…ë‹ˆë‹¤.","threads_edited_kor":"**ì•Œì¸ í•˜ì´ë¨¸ë³‘, ì´ì œ í”¼ í•œ ë°©ìš¸ë¡œ ê²€ì‚¬í•©ë‹ˆë‹¤: ë¬´ì—‡ì´ ë‹¬ë¼ì§ˆê¹Œìš”?**\n\nìµœê·¼ ë¯¸êµ­ ì‹í’ˆì˜ì•½êµ­(FDA)ì´ ê°„ë‹¨í•œ í˜ˆì•¡ ê²€ì‚¬ë¡œ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì„ ì§„ë‹¨í•˜ëŠ” ê²ƒì„ ìŠ¹ì¸í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì•Œì¸ í•˜ì´ë¨¸ë³‘ì„ ë°œê²¬í•˜ê³  ì¹˜ë£Œí•˜ëŠ” ë°©ì‹ì„ ì™„ì „íˆ ë°”ê¾¸ëŠ” íšê¸°ì ì¸ ì‚¬ê±´ì…ë‹ˆë‹¤.\n\n**ë¬´ì—‡ì´, ì™œ ì¤‘ìš”í•œê°€ìš”?**\n\nì´ì „ê¹Œì§€ ì•Œì¸ í•˜ì´ë¨¸ë³‘ì„ ì§„ë‹¨í•˜ë ¤ë©´ ë¹„ì‹¸ê³  ê³ í†µìŠ¤ëŸ¬ìš´ ê²€ì‚¬(ë‡Œ PET ì´¬ì˜, ì²™ìˆ˜ì•¡ ì±„ì·¨ ë“±)ë¥¼ ë°›ì•„ì•¼ í–ˆìŠµë‹ˆë‹¤. ì´ ë•Œë¬¸ì— ë§ì€ ì‚¬ëŒë“¤ì´ ê²€ì‚¬ë¥¼ êº¼ë ¸ê³ , ì´ˆê¸° ì¦ìƒì´ ìˆëŠ” í™˜ì 10ëª… ì¤‘ 9ëª…ì€ ì§„ë‹¨ì„ ë°›ì§€ ëª»í–ˆìŠµë‹ˆë‹¤.\n\ní•˜ì§€ë§Œ ì´ì œ ë™ë„¤ ë³‘ì›ì—ì„œ ê°„ë‹¨í•œ í˜ˆì•¡ ê²€ì‚¬ë§Œìœ¼ë¡œë„ ì•Œì¸ í•˜ì´ë¨¸ë³‘ ìœ„í—˜ì„ í™•ì¸í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë” ë§ì€ ì‚¬ëŒë“¤ì´ ì¡°ê¸°ì— ë³‘ì„ ë°œê²¬í•˜ê³  ì¹˜ë£Œë¥¼ ì‹œì‘í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆë‹¤ëŠ” ì˜ë¯¸ì´ë©°, ì œì•½ íšŒì‚¬ë“¤ì—ê²ŒëŠ” ê±°ëŒ€í•œ ìƒˆë¡œìš´ ì‹œì¥ì´ ì—´ë ¸ë‹¤ëŠ” ëœ»ì´ê¸°ë„ í•©ë‹ˆë‹¤.\n\n**ìƒˆë¡œìš´ ê²€ì‚¬ë¥¼ ë§Œë“œëŠ” ì£¼ìš” íšŒì‚¬ë“¤**\n\ní˜„ì¬ ë‘ ê°œì˜ ê²€ì‚¬ê°€ ì‹œì¥ì„ ì´ëŒê³  ìˆìŠµë‹ˆë‹¤.\n\n1.  **ë¡œìŠˆ & ì¼ë¼ì´ ë¦´ë¦¬ì˜ ê²€ì‚¬:** ë‘ ê±°ëŒ€ ì œì•½íšŒì‚¬ê°€ ì†ì„ ì¡ê³  ë§Œë“  ê²€ì‚¬ì…ë‹ˆë‹¤. ì´ ê²€ì‚¬ëŠ” 99%ì˜ ì •í™•ë„ë¡œ \"ì•Œì¸ í•˜ì´ë¨¸ë³‘ì´ ì•„ë‹˜\"ì„ í™•ì¸í•´ ì¤ë‹ˆë‹¤. ì¦‰, ë§ì€ í™˜ìë“¤ì´ ë¶ˆí•„ìš”í•˜ê³  ë¹„ì‹¼ ì¶”ê°€ ê²€ì‚¬ë¥¼ ë°›ì§€ ì•Šì•„ë„ ë˜ê²Œ ë§Œë“¤ì–´ ì˜ë£Œ ë¹„ìš©ì„ í¬ê²Œ ì¤„ì—¬ì¤ë‹ˆë‹¤. ë¡œìŠˆì—ê²ŒëŠ” ìƒˆë¡œìš´ ìˆ˜ìµì›ì´ ë˜ê³ , ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œë¥¼ ê°œë°œí•˜ëŠ” ì¼ë¼ì´ ë¦´ë¦¬ì—ê²ŒëŠ” ì•½ì´ í•„ìš”í•œ í™˜ìë¥¼ ë” ì‰½ê²Œ ì°¾ì„ ìˆ˜ ìˆëŠ” ë„êµ¬ê°€ ë©ë‹ˆë‹¤.\n\n2.  **í›„ì§€ë ˆë¹„ì˜¤ì˜ ê²€ì‚¬:** ì¼ë³¸ì˜ ì „ë¬¸ ë°”ì´ì˜¤ ê¸°ì—…ì´ ê°œë°œí–ˆìŠµë‹ˆë‹¤. ì´ ê²€ì‚¬ëŠ” \"ì•Œì¸ í•˜ì´ë¨¸ë³‘ì´ ì•„ë‹ˆë‹¤\"ë¼ê³  í™•ì¸í•˜ëŠ” ëŠ¥ë ¥ê³¼ \"ì•Œì¸ í•˜ì´ë¨¸ë³‘ì´ ë§ë‹¤\"ë¼ê³  í™•ì¸í•˜ëŠ” ëŠ¥ë ¥ì„ ëª¨ë‘ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ì˜ì‚¬ë“¤ì—ê²Œ ë” ëª…í™•í•œ ì •ë³´ë¥¼ ì œê³µí•  ìˆ˜ ìˆì–´ ì‹œì¥ì—ì„œ í° ì¸ê¸°ë¥¼ ëŒ ê°€ëŠ¥ì„±ì´ ìˆìŠµë‹ˆë‹¤.\n\n**ì£¼ì˜í•  ì : \"íšŒìƒ‰ ì§€ëŒ€\"**\n\nì´ëŸ¬í•œ ê²€ì‚¬ë“¤ì´ í•­ìƒ 'ì˜ˆ' ë˜ëŠ” 'ì•„ë‹ˆì˜¤'ë¡œ ëª…í™•í•œ ë‹µì„ ì£¼ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ë•Œë¡œëŠ” ê²°ê³¼ê°€ ì• ë§¤í•œ \"íšŒìƒ‰ ì§€ëŒ€\"ì— ì†í•˜ê¸°ë„ í•©ë‹ˆë‹¤. ì•ìœ¼ë¡œëŠ” ì´ íšŒìƒ‰ ì§€ëŒ€ë¥¼ ì¤„ì—¬ ë” ì •í™•í•˜ê³  í™•ì‹¤í•œ ê²°ê³¼ë¥¼ ì œê³µí•˜ëŠ” ê²€ì‚¬ê°€ ê²½ìŸì—ì„œ ì´ê¸°ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.\n\n**ê°€ì¥ í° ë³€í™”: ì¹˜ë£Œì œ ì‹œì¥ì´ ì—´ë¦½ë‹ˆë‹¤**\n\nì´ë²ˆ í˜ˆì•¡ ê²€ì‚¬ì˜ ê°€ì¥ ì¤‘ìš”í•œ ì ì€ ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œì™€ ì‹œë„ˆì§€ë¥¼ ë‚¸ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.\n\n*   **ì œì•½ íšŒì‚¬ì— ì°¾ì•„ì˜¨ ê¸°íšŒ:** ì§€ê¸ˆê¹Œì§€ ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œì˜ ê°€ì¥ í° ìˆ™ì œëŠ” 'ëˆ„êµ¬ì—ê²Œ' ì•½ì„ ì¨ì•¼ í• ì§€ ì¡°ê¸°ì— ì°¾ì•„ë‚´ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ì´ í˜ˆì•¡ ê²€ì‚¬ê°€ ê·¸ ë¬¸ì œë¥¼ í•´ê²°í•´ ì¤ë‹ˆë‹¤. ì´ì œ ì¼ë¼ì´ ë¦´ë¦¬ë‚˜ ë°”ì´ì˜¤ì   ê°™ì€ ì¹˜ë£Œì œ ê°œë°œ íšŒì‚¬ë“¤ì€ ì•½ì´ í•„ìš”í•œ í™˜ìë“¤ì„ í›¨ì”¬ ë” ë¹ ë¥´ê³  ë§ì´ ì°¾ì•„ë‚¼ ìˆ˜ ìˆê²Œ ë˜ì–´, ì•½ë¬¼ íŒë§¤ê°€ í¬ê²Œ ëŠ˜ì–´ë‚  ê²ƒì…ë‹ˆë‹¤.\n\n*   **ì§„ë‹¨ íšŒì‚¬ë“¤ì˜ ì„±ì¥:** ë‹¹ì—°íˆ ì´ ê²€ì‚¬ë¥¼ ë§Œë“  ë¡œìŠˆë‚˜ í›„ì§€ë ˆë¹„ì˜¤ ê°™ì€ íšŒì‚¬ë“¤ì€ ì§ì ‘ì ì¸ ìˆ˜í˜œë¥¼ ì…ê²Œ ë©ë‹ˆë‹¤.\n\n**ë¯¸ë˜ ì „ë§**\n\nì´ë²ˆ ìŠ¹ì¸ì€ ì‹œì‘ì— ë¶ˆê³¼í•©ë‹ˆë‹¤. ì•ìœ¼ë¡œ ë” ì •í™•í•˜ê³ , ë” ì´ë¥¸ ì‹œê¸°ì—, ì‹¬ì§€ì–´ ì¦ìƒì´ ë‚˜íƒ€ë‚˜ê¸° ëª‡ ë…„ ì „ì— ì•Œì¸ í•˜ì´ë¨¸ë³‘ì˜ ìœ„í—˜ì„ ì˜ˆì¸¡í•˜ëŠ” ë” ë°œì „ëœ ê²€ì‚¬ë“¤ì´ ê³„ì†í•´ì„œ ë“±ì¥í•  ê²ƒì…ë‹ˆë‹¤.\n\n**ê²°ë¡ **\n\nìƒˆë¡œìš´ ì•Œì¸ í•˜ì´ë¨¸ í˜ˆì•¡ ê²€ì‚¬ëŠ” ë‹¨ìˆœíˆ ìƒˆë¡œìš´ ì§„ë‹¨ ê¸°ìˆ ì´ ì•„ë‹™ë‹ˆë‹¤. ì´ê²ƒì€ ì•Œì¸ í•˜ì´ë¨¸ë³‘ ì¹˜ë£Œì˜ ì „ì²´ íŒë„ë¥¼ ë°”ê¾¸ëŠ” 'ì—´ì‡ 'ì…ë‹ˆë‹¤. ì´ ì—´ì‡  ë•ë¶„ì— ì§„ë‹¨ íšŒì‚¬ëŠ” ë¬¼ë¡ , ì¹˜ë£Œì œë¥¼ ë§Œë“œëŠ” ì œì•½ íšŒì‚¬ë“¤ê¹Œì§€ ì „ë¡€ ì—†ëŠ” ì„±ì¥ì˜ ê¸°íšŒë¥¼ ë§ì´í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤."}]